1. Home
  2. GAB vs NRIX Comparison

GAB vs NRIX Comparison

Compare GAB & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Equity Trust Inc. (The)

GAB

Gabelli Equity Trust Inc. (The)

HOLD

Current Price

$5.36

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$15.54

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAB
NRIX
Founded
1986
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GAB
NRIX
Price
$5.36
$15.54
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$30.58
AVG Volume (30 Days)
1.2M
996.4K
Earning Date
01-01-0001
04-10-2026
Dividend Yield
10.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,987,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$26.32
P/E Ratio
N/A
N/A
Revenue Growth
N/A
99.31
52 Week Low
$4.50
$8.18
52 Week High
$6.37
$22.50

Technical Indicators

Market Signals
Indicator
GAB
NRIX
Relative Strength Index (RSI) 29.73 50.71
Support Level N/A $14.31
Resistance Level $6.22 $16.47
Average True Range (ATR) 0.10 0.83
MACD -0.00 0.11
Stochastic Oscillator 13.28 67.87

Price Performance

Historical Comparison
GAB
NRIX

About GAB Gabelli Equity Trust Inc. (The)

Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: